share_log

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $29 Price Target

Moomoo 24/7 ·  Apr 23 13:11

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $29 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment